UNSPSC 51124005: Flecainide acetate

This classification denotes an anti-arrhythmia agent with the molecular formula C17H20F6N2O3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8U465Q1WQ, chemically known as n-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide but more generally known as flecainide acetate, which bears US NIH Compound Identifier 3356. European Medicines Agency schedules Flecainide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13894MIG.

Most nations, for tariff and trade purposes, schedule flecainide acetate under HS 29333999 and SITC 51574. As of Q4 2014, FLECAINIDE ACETATE remains US FDA's Preferred Term for this commodity. Flecainide acetate bears US NLM identifiers UMLS ID C0086303 and NCI Concept Code C499. SMILES: CC(=O)O.C1CC(C(CC1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F.

UNSPSC 51124005 Flecainide acetate, a Commodity code, identifies a specific pharmaceutical active ingredient procured by state and local government entities for emergency medical services and pharmacy benefit programs. State and local governments buy this medication primarily as part of broader advanced life support drug procurement for fire rescue services and through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions for generic pharmaceutical distribution. The code sees activity from city purchasing departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances that serve participating state and local facilities.

Recent solicitation activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) posted April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue in Hillsborough County, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation required four specific medication line items (including adenosine, epinephrine, labetalol, and diltiazem vials) with nine-month minimum expiration dates and firm pricing including all freight to Tampa. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to develop direct contracting arrangements outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation.